184 related articles for article (PubMed ID: 30997674)
21. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
22. Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Zhang Z; Qin T; Hu N; Zhang Y; Ke X; Chen Y; Wu D; Shi J; Fu L
Cancer Gene Ther; 2019 Feb; 26(1-2):17-25. PubMed ID: 29910468
[TBL] [Abstract][Full Text] [Related]
23. ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.
Yang X; Shi J; Zhang X; Zhang G; Zhang J; Yang S; Wang J; Ke X; Fu L
Biosci Rep; 2019 May; 39(5):. PubMed ID: 31028135
[TBL] [Abstract][Full Text] [Related]
24. High expression of MiR-98 is a good prognostic factor in acute myeloid leukemia patients treated with chemotherapy alone.
Hu N; Cheng Z; Pang Y; Zhao H; Chen L; Wang C; Qin T; Li Q; Han Y; Shi J; Fu L
J Cancer; 2019; 10(1):178-185. PubMed ID: 30662538
[TBL] [Abstract][Full Text] [Related]
25. CD45 correlates with adverse risk stratification, decreased treatment response and unfavorable survival profiles in elderly acute myeloid leukemia patients.
Guo L; Chen L; Wang H
Cancer Biomark; 2018; 23(3):455-463. PubMed ID: 30347598
[TBL] [Abstract][Full Text] [Related]
26. High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia.
Niu M; Feng Y; Zhang N; Shao T; Zhang H; Wang R; Yao Y; Yao R; Wu Q; Cao J; Liu X; Liu Y; Xu K
Cancer Cell Int; 2019; 19():122. PubMed ID: 31080363
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
[TBL] [Abstract][Full Text] [Related]
28. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognosis analysis of
Zhang T; Zhao Y; Zhao Y; Zhou J
Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
[No Abstract] [Full Text] [Related]
30. Prognostic value of the FUT family in acute myeloid leukemia.
Dai Y; Cheng Z; Pang Y; Jiao Y; Qian T; Quan L; Cui L; Liu Y; Si C; Chen J; Ye X; Chen J; Shi J; Wu D; Zhang X; Fu L
Cancer Gene Ther; 2020 Feb; 27(1-2):70-80. PubMed ID: 31209266
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognosis analysis of
Zhang TJ; Zhang LC; Xu ZJ; Zhou JD
Aging (Albany NY); 2020 Jun; 12(14):14677-14690. PubMed ID: 32597790
[TBL] [Abstract][Full Text] [Related]
34. High
Cheng Z; Dai Y; Pang Y; Jiao Y; Liu Y; Cui L; Qian T; Quan L; Cui W; Pan Y; Ye X; Shi J; Fu L
Cancer Biol Ther; 2019; 20(10):1314-1318. PubMed ID: 31306053
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of Wnt and Fzd gene families in acute myeloid leukaemia.
Dai Y; Cheng Z; Fricke DR; Zhao H; Huang W; Zhong Q; Zhu P; Zhang W; Wu Z; Lin Q; Zhu H; Liu Y; Qian T; Fu L; Cui L; Zeng T
J Cell Mol Med; 2021 Feb; 25(3):1456-1467. PubMed ID: 33417298
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia.
Cui L; Cheng Z; Liu Y; Dai Y; Pang Y; Jiao Y; Ke X; Cui W; Zhang Q; Shi J; Fu L
Cancer Gene Ther; 2020 Feb; 27(1-2):15-21. PubMed ID: 30578412
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of PAK family kinases in acute myeloid leukemia.
Quan L; Cheng Z; Dai Y; Jiao Y; Shi J; Fu L
Cancer Gene Ther; 2020 Feb; 27(1-2):30-37. PubMed ID: 30890765
[TBL] [Abstract][Full Text] [Related]
38. Postremission therapy for acute myeloid leukemia in the first remission.
Kim ST; Jung CW; Lee J; Kwon JM; Oh SY; Park BB; Lee HR; Kim HJ; Kim K; Kim WS; Ahn JS; Kang WK; Park K
Leuk Lymphoma; 2007 May; 48(5):937-43. PubMed ID: 17487738
[TBL] [Abstract][Full Text] [Related]
39. [Clinical features and curative effect analysis of patients with myeloid neoplasms and RUNX1 mutations].
Chen SF; Wang TZ; Jiang SH; Shen HJ; Xu Y; Zhou HF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):983-988. PubMed ID: 30612398
[No Abstract] [Full Text] [Related]
40. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S
Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
